<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030446</url>
  </required_header>
  <id_info>
    <org_study_id>I149</org_study_id>
    <secondary_id>CAN-NCIC-149</secondary_id>
    <secondary_id>CDR0000069166</secondary_id>
    <nct_id>NCT00030446</nct_id>
  </id_info>
  <brief_title>Erlotinib and Carboplatin in Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer</brief_title>
  <official_title>A Phase II Study Of OSI-774 (NSC 718781) Given In Combination With Carboplatin In Patients With Recurrent Epithelial Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Biological therapies such as erlotinib may interfere with the growth of tumor&#xD;
      cells and slow the growth of the tumor. Drugs used in chemotherapy use different ways to stop&#xD;
      tumor cells from dividing so they stop growing or die. Combining erlotinib with carboplatin&#xD;
      may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of combining erlotinib and carboplatin in&#xD;
      treating patients who have recurrent ovarian, fallopian tube, or primary peritoneal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the response rate in patients with recurrent ovarian epithelial, fallopian&#xD;
           tube, or primary peritoneal cancer treated with erlotinib and carboplatin.&#xD;
&#xD;
        -  Determine the duration of stable disease, time to progression, and response duration in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Correlate the level of epidermal growth factor receptor tumor expression with objective&#xD;
           tumor response in patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study. Patients are stratified according to response to prior&#xD;
      platinum-containing therapy (platinum-sensitive, defined as 6 months or more since prior&#xD;
      therapy with platinum agent [closed to accrual as of 2/13/2004], vs platinum-resistant,&#xD;
      defined as less than 6 months since prior therapy with platinum agent).&#xD;
&#xD;
      Patients receive carboplatin IV over 30 minutes on day 1 and oral erlotinib once daily on&#xD;
      days 1-21. Treatment repeats every 21 days for up to 6 courses. After the completion of 6&#xD;
      courses of therapy, patients with responsive or stable disease may continue to receive&#xD;
      erlotinib and carboplatin in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed at 4 weeks and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 23-60 patients (8-30 for platinum-sensitive stratum [closed to&#xD;
      accrual as of 2/13/2004] and 15-30 for platinum-resistant stratum) will be accrued for this&#xD;
      study within 15-23 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 10, 2002</start_date>
  <completion_date type="Actual">December 21, 2009</completion_date>
  <primary_completion_date type="Actual">February 11, 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">50</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed recurrent ovarian epithelial, fallopian tube, or primary&#xD;
             peritoneal cancer for which no standard curative therapy exists&#xD;
&#xD;
          -  At least 1 measurable lesion&#xD;
&#xD;
               -  At least 20 mm by x-ray, non-spiral CT scan, or physical exam OR at least 10 mm&#xD;
                  by spiral CT scan&#xD;
&#xD;
               -  Ascites and bone metastases not considered measurable disease&#xD;
&#xD;
          -  No abdominal adenocarcinoma of unknown origin or borderline ovarian tumor&#xD;
&#xD;
          -  No elevated CA 125 as only evidence of disease&#xD;
&#xD;
          -  At least 1 but no more than 2 prior chemotherapy regimens required&#xD;
&#xD;
               -  First regimen must have contained cisplatin or carboplatin&#xD;
&#xD;
               -  Switching platinum compounds due to disease progression or failure to respond is&#xD;
                  considered 2 regimens&#xD;
&#xD;
               -  Same regimen as first- and second-line therapy is considered 2 regimens&#xD;
&#xD;
          -  Responded to prior platinum-based first-line chemotherapy&#xD;
&#xD;
               -  No platinum-refractory disease&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than upper limit of normal (ULN)&#xD;
&#xD;
          -  AST/ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than ULN&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
        Gastrointestinal:&#xD;
&#xD;
          -  See Surgery&#xD;
&#xD;
          -  No GI tract disease resulting in an inability to take oral medication or requiring IV&#xD;
             alimentation&#xD;
&#xD;
          -  No uncontrolled inflammatory GI disease (e.g., Crohn's disease or ulcerative colitis)&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
        Ophthalmic:&#xD;
&#xD;
          -  No ocular inflammation or infection&#xD;
&#xD;
          -  No significant ophthalmologic abnormalities, including:&#xD;
&#xD;
               -  History of dry eye syndrome, Sj√∂gren's syndrome, or keratoconjunctivitis sicca&#xD;
&#xD;
               -  Severe exposure keratopathy&#xD;
&#xD;
               -  Disorders that might increase the risk for epithelium-related complications&#xD;
                  (e.g., bullous keratopathy, aniridia, severe chemical burns, or neutrophilic&#xD;
                  keratitis)&#xD;
&#xD;
               -  Congenital abnormality (e.g., Fuch's dystrophy)&#xD;
&#xD;
               -  Abnormal slit-lamp examination using a vital dye (e.g., fluorescein or&#xD;
                  Bengal-Rose)&#xD;
&#xD;
               -  Abnormal corneal sensitivity test (e.g., Schirmer test or similar tear production&#xD;
                  test)&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergic reaction to compounds of similar chemical or biological composition&#xD;
             to erlotinib&#xD;
&#xD;
          -  No other serious illness, medical condition, or significant neurologic or psychiatric&#xD;
             disorder that would preclude study therapy&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No grade 3 or greater drug-related neurotoxicity&#xD;
&#xD;
          -  No other malignancy within the past 5 years except adequately treated nonmelanoma skin&#xD;
             cancer or curatively treated carcinoma in situ of the cervix&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas)&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy (except low-dose palliative radiotherapy)&#xD;
             and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 3 weeks since prior major surgery (wound healing must have occurred)&#xD;
&#xD;
          -  No prior surgical procedures affecting gastrointestinal (GI) absorption&#xD;
&#xD;
          -  No concurrent ophthalmic surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No prior therapy targeting epidermal growth factor receptor&#xD;
&#xD;
          -  No other concurrent anticancer therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  Concurrent oral anticoagulants (e.g., warfarin) allowed provided INR is monitored&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hal W. Hirte, MD, FRCP(C)</last_name>
    <role>Study Chair</role>
    <affiliation>Margaret and Charles Juravinski Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tom Baker Cancer Center - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Science Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Margaret and Charles Juravinski Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Notre- Dame du CHUM</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4L 2M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Hirte H, Oza A, Hoskins P, et al.: Phase II study of OSI-774 given in combination with carboplatin in patients (pts) with recurrent epithelial ovarian cancer (EOC): NCIC CTG IND.149. [Abstract] European Journal of Cancer Supplements 1 (5): A-159, S51, 2003.</citation>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>February 14, 2002</study_first_submitted>
  <study_first_submitted_qc>June 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2003</study_first_posted>
  <last_update_submitted>April 6, 2020</last_update_submitted>
  <last_update_submitted_qc>April 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>fallopian tube cancer</keyword>
  <keyword>peritoneal cavity cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

